EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Disease burden and eosinophilic phenotype in Chinese patients with moderate-to-severe asthma: Baseline analysis of a prospective, multicenter study (PRESENT)

Li Yu iD, Jian He, Yuewen Jiang, Gang Wang, Xin Feng, Lixiu Chen, Kewu Huang, Haiyan Wu, Li Zhen, Jie Cao, Zuoyan Li, Zhongmin Qiu iD

Therapeutic Advances in Respiratory Disease · 2026-08 · 20

DOI: 10.1177/17534666261475564 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 14.08.2026. Verfasst von Li Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Asthma, Eosinophils, Anti-Asthmatic Agents, Adrenal Cortex Hormones. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asthma is a common respiratory disease with a high disease burden in China. The patient population with severe asthma remains largely unexplored.

Objectives

To describe the disease burden, treatment pattern and eosinophilic phenotype of Chinese patients with moderate-to-severe asthma.

Design

This is a retrospective baseline analysis of the real-world, observational, multicenter PRESENT study (NCT06422663).

Methods

Patients receiving Global Initiative for Asthma Step 3–5 treatment were categorized into protocol-specified severe asthma (uncontrolled asthma with medium-dose inhaled corticosteroids [ICS], or asthma with high-dose ICS) and moderate asthma subgroups. This baseline analysis reported patient characteristics, disease burden, treatment patterns, eosinophilic phenotype and testing rates of biomarkers at enrolment. Disease burden was assessed by historical asthma exacerbation rate within the past year, Asthma Control Test (ACT) score and lung function.

Results

Of the 498 patients included, 203 (40.8%) were identified as having protocol-specified severe asthma. Notable disease burden was observed, as reflected by the high proportion of patients experiencing asthma exacerbation (severe asthma: 35.0%; moderate asthma: 14.6%), low ACT score (mean [SD]: severe asthma: 17.4 [3.8]; moderate asthma: 20.6 [3.7]) and declined pre-bronchodilator forced expiratory volume in one second (pre-BD FEV 1 ; median [interquartile range]: severe asthma: 2.0 [1.5, 2.5]; moderate asthma: 2.2 [1.7, 2.8]). Overall, testing rates of blood eosinophil (EOS) were 25.3% (in the past seven days), 49.0% (in the past three months) and 68.9% (in the past one year). Among patients who tested EOS once and twice in the past one year, 62.5% (180/288) and 76.4% (42/55) had blood EOS counts ≥150 cells/μL, respectively. Testing rates of different biomarkers varied but were generally low.

Conclusion

Notable disease burden and sub-optimal management were observed in Chinese patients with moderate-to-severe asthma. Biomarker-based phenotyping of severe asthma was unsatisfactory. Treatment escalation and routine monitoring of blood EOS level might be considered. Registration ClinicalTrials.gov , NCT06422663, registered on March 19, 2024, https://clinicaltrials.gov/study/NCT06422663 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaEosinophilsAnti-Asthmatic AgentsAdrenal Cortex HormonesLungHumansFemaleSeverity of Illness IndexMalePhenotypeChinaMiddle AgedProspective StudiesRetrospective StudiesAdultAdministration, InhalationDisease ProgressionTreatment OutcomeCost of IllnessAgedTime FactorsEast Asian People

Stichwörter der Autor:innen

Chinadisease burdeneosinophilsreal-worldsevere asthma

Substanzen

Anti-Asthmatic AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Pulmonary and Critical Care Medicine, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, China.
  • Department of Pulmonary and Critical Care Medicine, Qiyang People's Hospital, Yongzhou, China.
  • Department of Pulmonary and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Pulmonary and Critical Care Medicine, Nanbu People's Hospital, Nanchong, China.
  • Department of Pulmonary and Critical Care Medicine, Zhangjiagang First People's Hospital, Zhangjiagang, China.

ORCID-Profile: Li Yu, Zhongmin Qiu

Förderung

  • AstraZeneca China

Zitieren

APA

Yu, L., He, J., Jiang, Y., Wang, G., Feng, X., Chen, L., Huang, K., Wu, H., Zhen, L., Cao, J., Li, Z., & Qiu, Z. (2026). Disease burden and eosinophilic phenotype in Chinese patients with moderate-to-severe asthma: Baseline analysis of a prospective, multicenter study (PRESENT). Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261475564

Vancouver

Yu L, He J, Jiang Y, Wang G, Feng X, Chen L, et al. Disease burden and eosinophilic phenotype in Chinese patients with moderate-to-severe asthma: Baseline analysis of a prospective, multicenter study (PRESENT). Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261475564

BibTeX
@article{Yu2026,
  author = {Yu, Li and He, Jian and Jiang, Yuewen and Wang, Gang and Feng, Xin and Chen, Lixiu and Huang, Kewu and Wu, Haiyan and Zhen, Li and Cao, Jie and Li, Zuoyan and Qiu, Zhongmin},
  title = {Disease burden and eosinophilic phenotype in Chinese patients with moderate-to-severe asthma: Baseline analysis of a prospective, multicenter study (PRESENT)},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17534666261475564}
}
Kostenlos starten →